| Name | Title | Contact Details |
|---|
Regenstrief Institute, Inc., an international leader in electronic medical records and health care data integration, is a medical research and development organization focused on improving quality of care, efficiency of health care delivery, and enhancing patient outcomes.
Sirona Dental Systems, Inc. (Sirona) is a manufacturer of dental equipment. Sirona focuses on developing innovative systems and solutions for dentists globally.
For over 25 years, Guaranteed Returns has provided pharmaceutical return services to hospital, government, independent retail, chain-store, LTC, Mail-Order and clinic pharmacies. Local GRx on-site service representatives are highly valued by customers for their professionalism, trustworthiness and for “going above and beyond”. Guaranteed Returns puts their longevity and industry knowledge to work to obtain the maximum amount of credits for every pharmacy return. GRx concentrates on providing pharmaceutical return solutions that address all aspects of the business, beginning with the manufacturer, through crediting the customer. Business review consultations, inventory management assistance and an unbeatable customer service department are just a few of the attributes that customers say sets GRx apart. Their flagship program, ReverseLink One™ has been branded as “the most cost effective return goods program ever to be offered by any 3rd party returns company”. Guaranteed Returns is dedicated to making pharmaceutical returns as simple as possible for customers while attaining the maximum amount of credits. Guaranteed Returns puts their 25 years of knowledge to work every day – continually investing in new programs, technologies and people - which is why GRx delivers Service You Can Count On.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
St Ann's Home is a Methuen, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.